As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Public markets are showing early signs of reopening, as Q4 2025 saw a 157% increase in IPO deal volume compared to Q4 2024.

MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (GUD:CA) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America ...

Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ...

MUMBAI, May 16 (Reuters) - Indian drugmaker Glenmark Pharmaceuticals said on Monday its unit has signed a licensing agreement with France's Sanofi to develop and commercialise a novel monoclonal ...

- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe - BridgeBio to receive royalties ...

The MarketWatch News Department was not involved in the creation of this content. SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, ...

Through the agreement, Forward Pharma will provide Biogen an irrevocable license to its intellectual property. The two drugmakers are involved in ongoing disputes over patents for dimethyl fumarate — ...

STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015 (Terclara®) in ...

China's pharmaceutical industry has been on a mission to transform itself from a producer of cloned drugs to a global pioneer of new therapies. As those efforts start to bear fruit, the firms are ...